Uvi Cancino Ramos

Uvi Cancino Ramos

Auto-generated profile, based on publicly available information

Uvi Cancino Ramos

Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Pediatría, Ciudad de México, México

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2021 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
MHMarylin Acuña Hernandez
Marylin Acuña Hernandez
LOLiset Sanchez Orduz
Liset Sanchez Orduz
URUvi Cancino Ramos
Uvi Cancino Ramos
PAPaola Vallejo Armenta
Paola Vallejo Armenta
LBLeonardo Cadavid Blanco
Leonardo Cadavid Blanco

15 September 2022 in PROBLEMS OF ENDOCRINE PATHOLOGY
Verified
Journal Article
Open access
PDF file
MHMarylin Acuña Hernandez
Marylin Acuña Hernandez
PAPaola Vallejo Armenta
Paola Vallejo Armenta
URUvi Cancino Ramos
Uvi Cancino Ramos
LOLiset Sánchez Ordúz
Liset Sánchez Ordúz
Pamela Casanova-TriviñoPamela Casanova-Triviño
Pamela Casanova-Triviño
LBLeonardo Cadavid Blanco
Leonardo Cadavid Blanco
Thyroid cancer is a common endocrinological malignancy worldwide, accounting for 3% of the global incidence of all cancers. Meta-analyses, systematic reviews, and descriptive reviews mention the use of positron emission tomography / computed tomography (PET/CT) as an alternative to morphological imaging such as computed tomography or magnetic resonance imaging to clarify the diagnosis. The aim: analysis of positron emission tomography/computed tomography tracers in the differential diagnosis of thyroid carcinomas. Materials and methods: Review about PET/CT tracers different than 2-[18F] fluorodeoxyglucose (FDG) in patients with diagnosed differentiated thyroid carcinoma. Evidence Synthesis: PET/CT is an alternative to morphological diagnosis imaging when is inconclusive or negative due to the suspicion of tumor persistence or recurrence, elevation of tumor markers, dedifferentiation thyroid carcinoma, non-conventional therapeutic options. 2-[18F] FDG is the most uses a tracer, but there are scenarios where can be negative or inconclusive, for this reason, in recent years other PET tracers have been used: [124I] NaI, [18F] Tetrafluoroborate, [68Ga] Ga-NOTE-PRGD2 or [18F] AIF-NOTE-PRGD2, [68Ga] Ga-DOTA-FAPI, [18F] Fluorocholine or [11C] C-Choline, [18F] or [68Ga] Ga-PSMA, [68Ga] Ga DOTA-TATE/TOC/NOC/LAN, [18F]-FAZA, L-[methyl-11C] Methionine and [89Zr] DFO-PAS200-Fab. Conclusions. There are multiple radiopharmaceuticals different than 2-[18F] FDG, which can be adequate in the context of differentiated thyroid carcinoma: 2-[18F] FDG PET/CT negative, TENIS syndrome, radioiodine-refractory thyroid cancer suspected, thyroid dedifferentiated carcinoma, and some cases theragnostic tools.